KLRK1 and neoplasm: In contrast, NK ligand-bearing tumor cells induce downregulation of the expression of active receptors, such as NKG2D, and inhibit degranulation on NK cells, resulting in compromised cytotoxicity and reduced levels of antitumor immune surveillance and lytic proteins (52).